The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; none of the 1 sources its claims cite is checked for support yet.
Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers
Open accessAbstract
Synapse deterioration underlying severe memory loss in early Alzheimer's disease (AD) is thought to be caused by soluble amyloid beta (Aβ) oligomers. Mechanistically, soluble Aβ oligomers, also referred to as Aβ-derived diffusible ligands (ADDLs), act as highly specific pathogenic ligands, binding to sites localized at particular synapses. This binding triggers oxidative stress, loss of synaptic spines, and ectopic redistribution of receptors critical to plasticity and memory. We report here the existence of a protective mechanism that naturally shields synapses against ADDL-induced deterioration. Synapse pathology was investigated in mature cultures of hippocampal neurons. Before spine loss, ADDLs caused major downregulation of plasma membrane insulin receptors (IRs), via a mechanism sensitive to calcium calmodulin-dependent kinase II (CaMKII) and casein kinase II (CK2) inhibition. Most significantly, this loss of surface IRs, and ADDL-induced oxidative stress and synaptic spine deterioration, could be completely prevented by insulin. At submaximal insulin doses, protection was potentiated by rosiglitazone, an insulin-sensitizing drug used to treat type 2 diabetes. The mechanism of insulin protection entailed a marked reduction in pathogenic ADDL binding. Surprisingly, insulin failed to block ADDL binding when IR tyrosine kinase activity was inhibited; in fact, a significant increase in binding was caused by IR inhibition. The protective role of insulin thus derives from IR signaling-dependent downregulation of ADDL binding sites rather than ligand competition. The finding that synapse vulnerability to ADDLs can be mitigated by insulin suggests that bolstering brain insulin signaling, which can decline with aging and diabetes, could have significant potential to slow or deter AD pathogenesis.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In mature hippocampal cultures, insulin signaling prevented Aβ oligomer (ADDL) binding, oxidative stress, insulin receptor loss, and spine degeneration, with protection requiring insulin receptor tyrosine kinase activity rather than simple ligand competition. Rosiglitazone potentiated submaximal insulin’s protection, suggesting that enhancing CNS insulin signaling may defend synapses against Alzheimer’s-linked toxins.
Key findings
- ADDLs caused loss of surface insulin receptors (IRs): surface-exposed IR levels decreased by 22% after 30 min and 68% after 3 h of exposure to 100 nM ADDLs.
- The CK2 inhibitor DMAT completely blocked ADDL-induced loss of both IRs and NMDA receptors; the CaMKII inhibitor KN93 afforded partial protection.
- Insulin at 100 nM partially prevented and 1 μM completely blocked ADDL-induced dendritic IR loss; 1 μM insulin caused a major (≈70%) blockade of ADDL binding, and 100 nM insulin + 10 μM rosiglitazone produced IR levels similar to control or 1 μM insulin.
- Insulin prevented ADDL-induced oxidative stress and 24-h spine degeneration; protection required IR activity, because AG1024 (5 μM) abolished insulin’s ability to block ADDL binding and increased binding when added alone or with insulin.
Methods
- Primary mature hippocampal neuronal cultures were used after 21 DIV and treated at 37 °C for 3 h with 100 nM ADDLs or vehicle; insulin (100 nM or 1 μM) or rosiglitazone (10 μM) was added 30 min before ADDLs, and AG1024 (5 μM) was added 30 min before insulin.
- ADDLs were prepared from Aβ1–42; outcomes were assessed by surface biotinylation/Western blot, immunocytochemistry with IRα and NU4 anti-ADDL antibodies, phalloidin labeling of spines, and dihydroethidium (DHE) for reactive oxygen species.
- Immunofluorescence intensities were analyzed with NIH ImageJ.
Limitations
- The paper states that the nature of the ADDL binding sites “has yet to be determined” and that future identification of proteins lost from the membrane in response to insulin could provide insight into them.
- Evident from the text: all experiments were performed in mature hippocampal neuronal cultures; no in vivo or human data are reported in this study.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 1 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that DMAT, a CK2 inhibitor, completely blocked ADDL-induced loss of both IRs and NMDARs from the dendrites of hippocampal neurons”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Results > Casein Kinase 2 (CK2) and Ca2+/Calmodulin-Dependent Kinase II (CaMKII) Mediate ADDL-Induced Loss of IRs and NMDA subtype glutamate receptors (NMDARs).
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results are consistent with the notion that ADDLs have a selective impact in accelerating the endocytosis of particular surface proteins, such as IRs.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Results > ADDLs Induce Loss of IRs from Neuronal Surfaces.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Decreased binding is the result of downregulation of ADDL binding sites through a mechanism requiring insulin receptor (IR) tyrosine kinase activity.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Results here support the hypothesis that the beneficial effect of insulin in AD derives at least in part from an acute decrease in ADDL synaptotoxicity.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A plausible mechanism of protection is provided by the current finding that rosiglitazone potentiates the ability of insulin to protect synapses against ADDLs.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, ADDL-induced loss of IRs might represent an important early mechanism underlying memory impairment and other pathological features of AD.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Results > Casein Kinase 2 (CK2) and Ca2+/Calmodulin-Dependent Kinase II (CaMKII) Mediate ADDL-Induced Loss of IRs and NMDA subtype glutamate receptors (NMDARs).
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Given that insulin protects neurons against AD-causing neurotoxins, it follows that dysfunctional CNS insulin signaling would be an AD risk factor.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“indicating potentiation of insulin protection by rosiglitazone.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Results > Rosiglitazone Potentiates the Neuroprotective Action of Insulin.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Results strongly support the hypothesis that insulin signaling plays a role in defending CNS neurons against AD and provide a disease-specific basis for treatments based on stimulating CNS insulin pathways.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The finding that synapse vulnerability to ADDLs can be mitigated by insulin suggests that bolstering brain insulin signaling, which can decline with aging and diabetes, could have significant potential to slow or deter AD pathogenesis.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 7
- Probably not a substantial claim. 1
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In fact, AG1024 caused significant increases in neuronal ADDL binding both when AG1024 was added alone and in the presence of exogenous insulin.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Results > Protection by Insulin Requires IR Activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“We have identified a unique molecular mechanism that protects CNS neurons against ADDLs, soluble neurotoxins putatively responsible for the synaptic deterioration underlying Alzheimer's memory failure.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, physiological insulin and pathological ADDLs negatively regulate the abundance of each other's binding sites, creating a competitive balance between synapse survival and degeneration.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus the mechanism of protection does not involve simple competition between ADDLs and insulin for a common binding site on the neuronal surface, but rather is a signaling-dependent downregulation of ADDL binding sites.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Results show that insulin blocks ADDL binding to synapses, thereby preventing the ensuing neurotoxicity.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This indicates that loss of insulin receptors precedes and is not a consequence of overall collapse and retraction of synaptic spines.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Results > Insulin Prevents ADDL-Induced Synapse Loss.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“An elevated risk for AD also exists in type 2 diabetes patients, who manifest deficient CNS insulin signaling.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
What the sources say
- Not checked yetcites [31] Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4:147–152. doi: 10.2174/156720507780362137. [[DOI](https://doi.org/10.2174/156720507780362137)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/17430239/)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Curr%20Alzheimer%20Res&title=Insulin%20resistance%20and%20Alzheimer's%20disease%20pathogenesis:%20potential%20mechanisms%20and%20implications%20for%20treatment&author=S%20Craft&volume=4&publication_year=2007&pages=147-152&pmid=17430239&do source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Insulin signaling downregulates ADDL binding, while ADDLs downregulate IRs.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Internalization occurs by a mechanism mediated by casein kinase 2 (CK2) and Ca2+/calmodulin-dependent kinase 2 (CaMK II), which also are involved in ADDL-induced internalization of NMDA receptors (De Felice et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
In the citing paper
“Aβ oligomers induce a striking redistribution of IRs, causing their internalization from dendritic membranes and accumulation in the cell body. This renders neurons insulin resistant (De Felice et al., 2009; De Felice et al., 2008; Zhao et al., 2008).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
In the citing paper
“insulin itself blocks the pathological binding of Aβ oligomers and the resulting redistribution of IRs and synapse loss (De Felice et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
In the citing paper
“Clustering of oligomers at synapses, moreover, shows a cause-and-effect relationship with characteristic Alzheimer neuropathologies. AD type tau hyperphosphorylation (De Felice et al., 2008), redistribution of insulin receptors (De Felice et al., 2009; Zhao et al., 2008), spine loss (Lacor et al., 2007) and oxidative stress (De Felice et al., 2007; Decker et al., 2010a) are manifest exclusively in”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
In the citing paper
“pharmacological experiments indicate involvement of CaMKII and casein kinase II (De Felice et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
In the citing paper
“Several neuronal receptors have been proposed as mediating the effect of Aβ on synaptic plasticity and memory, including the α-7-nicotinic (16), glutamatergic (39–40), and insulin (14) receptors.”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [14]
In the citing paper
“deteriorations in the clearance and degradation of Aβ as a result of impaired insulin signalling are discussed as a mechanism that increases the risk of AD 135 and may be improved by insulin administration.136,137”
From Intranasal insulin (2021) · cites this paper as [136]
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedSoluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citationPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 1×
“We recently reported that ADDLs cause a major loss of IRs from neuronal dendrites (9), in harmony with the impact of ADDLs on other essential plasticity-related neuronal molecules such as N-methylD-aspartate (NMDA) receptors (18, 20).”
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 655
Panayiotou, E., Fella, E., Andreou, S., Papacharalambous, R., Gerasimou, P., Costeas, P., Angeli, S., Kousiappa, I., Papacostas, S., & Kyriakides, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225417 · Cited by 26
Does Insulin Therapy for Type 1 Diabetes Mellitus Protect Against Alzheimer's Disease?
Rdzak, G. M., & Abdelghany, O. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1494 · Cited by 25
“Insulin prevents ADDL-induced neuronal deterioration by signaling-dependent downregulation of ADDL binding sites in mature cultures of hippocampal neurons.(33) A schematic representation of how insulin helps to reduce amyloid plaques and neuronal deterioration can be found in Figure 2.”
BackgroundRial, D., Piermartiri, T., Duarte, F. S., Tasca, C. I., Walz, R., & Prediger, R. D. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.04.034 · Cited by 25
Zhang, B., Tang, X. C., & Zhang, H. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23201 · Cited by 26
“To increase sensitivity of neuronal IGF-1R to IGF-1, the culture medium of hippocampal neurons was changed to neurobasal medium without B27 supplement for 3–4 hr before treatments, as described previously (De Felice et al., 2009).”
MethodDiChiara, T., DiNunno, N., Clark, J. R., Bu, R. L., Cline, E. N., Rollins, M. G., Gong, Y., Brody, D. L., Sligar, S. G., Velasco, P. T., et al. (2017) · PubMed · Cited by 25
Self-citationMcNay, E. C., & Recknagel, A. K. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.11.001 · Cited by 26
Natural products targeting amyloid-β oligomer neurotoxicity in Alzheimer's disease
Gonçalves, P. B., Sodero, A. C. R., & Cordeiro, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116684 · Cited by 26
Xenos, D., Mancinetti, F., Mecocci, P., & Boccardi, V. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102955 · Cited by 26
Therapeutic Strategies Aimed at Improving Neuroplasticity in Alzheimer Disease
Colavitta, M. F., & Barrantes, F. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082052 · Cited by 25
Diabetes, Insulin and Alzheimer's Disease
Craft, S., & Christen, Y. (2010) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-642-04300-0 · Cited by 24
Wang, J., Liu, Y., Cheng, X., Zhang, X., Liu, F., Liu, G., Qiao, S., Ni, M., Zhou, W., Zhang, Y., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161079 · Cited by 24
New drug treatments show neuroprotective effects in Alzheimer′s and Parkinson′s diseases
Hölscher, C. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.145342 · Cited by 25
“In vitro cell culture experiments showed that oligomers bind to and activate receptors which are then taken up into the cell (Zhao et al., 2008; De Felice et al., 2009).”
Quesnel, M. J., Labonté, A., Picard, C., Zetterberg, H., Blennow, K., Brinkmalm, A., Villeneuve, S., Poirier, J., Initiative, A. D. N., Weiner, M. W., et al. (2023) · Brain · doi:10.1093/brain/awad398 · Cited by 24
Alzheimer disease: update on basic mechanisms.
Bi, X. (2010) · PubMed · Cited by 24
Song, J., Kang, S.-M., Kim, E., Kim, C. H., Song, H., & Lee, J. E. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.072 · Cited by 23
Diabesity and Brain Energy Metabolism: The Case of Alzheimer’s Disease
Cardoso, S., Seiça, R. M. F., & Moreira, P. I. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-63260-5_5 · Cited by 24
Hyperinsulinemia or Insulin Resistance: What Impacts the Progression of Alzheimer’s Disease?
Hegde, V. K., Dhurandhar, N. V., & Reddy, P. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190808 · Cited by 22
Alexopoulos, P., Guo, L., Tsolakidou, A. F., Kratzer, M., Grimmer, T., Westerteicher, C., Jiang, M., Bujo, H., Diehl‐Schmid, J., Kurz, A., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110983 · Cited by 25
“According to findings of cell culture studies, they attach to synapses in the central nervous system and inhibit long-term potentiation, enhance long term depression, induce oxidative stress and abnormal phosphorylation of tau, and subsequently foster axonal degeneration [5–7].”
Current and Future Nano-Carrier-Based Approaches in the Treatment of Alzheimer’s Disease
Kumar, A., Sudevan, S. T., Nair, A. S., Singh, A. K., Kumar, S., Jose, J., Behl, T., Mangalathillam, S., Mathew, B., & Kim, H. (2023) · Brain Sciences · doi:10.3390/brainsci13020213 · Cited by 26
“According to the in vitro evaluation, Rosiglitazone displays a partial neuroprotective effect, while with the combination of insulin it shows good neuroprotective effects [20].”
BackgroundFarzampour, S., Majdi, A., & Sadigh‐Eteghad, S. (2016) · Physiology International · doi:10.1556/2060.103.2016.3.7 · Cited by 22
Molecular Connection Between Diabetes and Dementia
Chen, Y., Yu, Q., & Gong, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3540-2_6 · Cited by 24
Kwon, B., Gamache, T., Lee, H., & Querfurth, H. W. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.012 · Cited by 23
Idrees, T., Castro-Revoredo, I. A., Oh, H. D., Gavaller, M. D., Zabala, Z., Moreno, E., Moazzami, B., Galindo, R. J., Vellanki, P., Cabb, E., et al. (2024) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2024.01.031 · Cited by 22
Affuso, F., Micillo, F., & Fazio, S. (2024) · Biomedicines · doi:10.3390/biomedicines12081888 · Cited by 25
“Animal studies have Insulin and IGF1 increase the clearance of A β in the brain of mice and partially restore A β oligomer damage in hippocampus cells line [80], thereby halting the loss of synapses in neurons [81,82]. that enhance the development of amyloid plaques and neurodegeneration [79].”
BackgroundEpigenetic regulation of synaptic disorder in Alzheimer’s disease
Chen, Z., Wu, M., Lai, Q., Zhou, W., Wen, X., & Yin, X. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.888014 · Cited by 22
Arcos, J., Grünenwald, F., Sepúlveda, D., Jerez, C., Urbina, V., Huerta, T., Troncoso-Escudero, P., Tirado, D., Perez, A., Díaz‐Espinoza, R., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01734-1 · Cited by 24
Fessel, W. J. (2017) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317517698790 · Cited by 21
Therapies for Alzheimer’s disease: a metabolic perspective
Domingues, R., Pereira, C., Cruz, M. T., & Silva, A. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.01.011 · Cited by 21
Han, X., Ma, Y., Liu, X., Wang, L., Qi, S., Zhang, Q., & Du, Y. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0803-1 · Cited by 20
Exploring the New Horizon of AdipoQ in Obesity-Related Alzheimer’s Dementia
Uddin, M. S., Rahman, M. M., Sufian, M. A., Jeandet, P., Ashraf, G. M., Bin-Jumah, M. N., Mousa, S. A., Abdel‐Daim, M. M., Akhtar, M. F., Saleem, A., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.567678 · Cited by 21
Yang, J. J. (2022) · Acta Neurologica Belgica · doi:10.1007/s13760-022-01907-2 · Cited by 21
The Association Between Diabetes and Dementia Among Elderly Individuals
Sherzai, D., Sherzai, A. Z., Lui, K., Pan, D., Chiou, D., Bazargan, M., & Shaheen, M. A. (2016) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988715627016 · Cited by 21
“Exogenous insulin has been postulated to protect against the pathogenic binding of b-amyloid onto neuronal synapses in the brain.(21) A recent randomized controlled trial with intranasal insulin therapy also demonstrated that insulin protected against cognitive decline in participants with AD.”
BackgroundMahakizadeh, S., Mokhtari, T., Navaee, F., Poorhassan, M., Tajik, A., & Hassanzadeh, G. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101744 · Cited by 20
Intranasal administration: a prospective drug delivery route to the brain
Privalova, A. M., Gulyaeva, N. V., & Букреева, Т. В. (2012) · Neurochemical Journal · doi:10.1134/s1819712412020080 · Cited by 21
Gyengési, E., Andrews, Z. B., Paxinos, G., & Záborszky, L. (2013) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.01.009 · Cited by 19
“Since insulin can protect -amyloid-induced synaptic loss in an AD model, the presence of Scgn in pancreatic -cells points to common function in endocrine and the nervous systems, which may underlie the pathogenesis of AD and type II diabetes (De Felice et al., 2009).”
BackgroundMeng, X., Du, H., Li, D., Guo, Y., Luo, P., Pan, L., Kan, R., Yu, P., Xiang, Y., Mao, B., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70089 · Cited by 24
Is interaction of amyloid β-peptides with metals involved in cognitive activity?
Tamano, H., & Takeda, A. (2015) · Metallomics · doi:10.1039/c5mt00076a · Cited by 19
Dandona, P., Mohamed, I., Ghanim, H., Sia, C. L., Dhindsa, S., Dandona, S., Makdissi, A., & Chaudhuri, A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2961 · Cited by 19
Heat shock response and insulin-associated neurodegeneration
Urban, M. J., Dobrowsky, R. T., & Blagg, B. S. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.11.001 · Cited by 19
Soluble state high resolution atomic force microscopy study of Alzheimer’s β-amyloid oligomers
Shekhawat, G. S., Lambert, M. P., Sharma, S., Velasco, P. T., Viola, K. L., Klein, W. L., & Dravid, V. P. (2009) · Applied Physics Letters · doi:10.1063/1.3251779 · Cited by 19
Self-citationThe Rationale for Insulin Therapy in Alzheimer’s Disease
Ribarič, S. (2016) · Molecules · doi:10.3390/molecules21060689 · Cited by 20
“The hippocampus is rich with insulin receptors that are localized mainly to nerve synapses [111,252].”
BackgroundAlzheimer’s disease: Key developments support promising perspectives for therapy
Meldolesi, J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104316 · Cited by 19
Baram, M., & Miller, Y. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00645 · Cited by 18
Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds
Remnestål, J., Bergström, S., Olofsson, J., Sjöstedt, E., Uhlén, M., Blennow, K., Zetterberg, H., Zettergren, A., Kern, S., Skoog, I. G., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00789-5 · Cited by 17
Recent developments in the chemical biology of amyloid-β oligomer targeting
Wang, Y., Chen, J., Gao, F., Hu, M., & Wang, X. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob00509g · Cited by 20
Connecting Type 2 diabetes to Alzheimer’s disease
Felice, F. G. D. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.864824 · Cited by 17
Self-citationLevistolide A Attenuates Alzheimer's Pathology Through Activation of the PPARγ Pathway
Qu, X., Guan, P., Han, L., Wang, Z., & Huang, X. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00943-1 · Cited by 18
Lin, H., Chung, C., Chen, L., Wang, J., Chen, C., Huang, K., Tsai, M.-H., Chien, W., & Lin, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-33674-2 · Cited by 17
Chan, E. S., Chen, C., Soong, T. W., & Wong, B. (2018) · NeuroMolecular Medicine · doi:10.1007/s12017-018-8480-3 · Cited by 14
Gupta, S. N., Singhal, N. K., Ganesh, S., & Sandhir, R. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666181114163515 · Cited by 16
Frederikse, P. H., Nandanoor, A., & Kasinathan, C. (2015) · Current Eye Research · doi:10.3109/02713683.2014.997886 · Cited by 16
Lin, C., Nicol, C. J. B., Cheng, Y., Chen, S., Yen, C., Huang, R., & Chiang, M. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.06.033 · Cited by 16
Kamei, N. (2017) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.17-00138 · Cited by 15
Nonesterified fatty acids, cognitive decline, and dementia
Mukamal, K. J. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000656 · Cited by 16
Chambers, A., Bury, J. J., Minett, T., Richardson, C. D., Brayne, C., Ince, P. G., Shaw, P. J., Garwood, C. J., Heath, P. R., Simpson, J. E., et al. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa064 · Cited by 15
Qin, G., Dong, Y., Liu, Z., Gong, Z., Gao, C., Zheng, M., Tian, M., He, Y., Zhong, L., & Wang, P. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00540-0 · Cited by 14
Saffron as a promising therapy for diabetes and Alzheimer's disease: mechanistic insights
Sanaie, S., Nikanfar, S., Yousefi, Z., Azizi-Zeinalhajlou, A., Sadigh‐Eteghad, S., Araj‐Khodaei, M., Ayati, M. H., & Andalib, S. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01059-5 · Cited by 15
Insulin induces neurite outgrowth via SIRT1 in SH-SY5Y cells
Liu, Y., Yao, Z., Zhang, L., Zhu, H., Deng, W., & Qin, C. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.01.034 · Cited by 15
Insulin resistance in the brain: A new therapeutic target for Alzheimer's disease
Umegaki, H. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12027 · Cited by 15
Metformin improves memory via AMPK/mTOR-dependent route in a rat model of Alzheimer's disease.
Mehraban, R. A. M., Babaei, P., Rohampour, K., Jafari, A., & Golipoor, Z. (2024) · PubMed Central · doi:10.22038/ijbms.2023.73075.15879 · Cited by 14
Lazard, D., Vardi, P., & Bloch, K. O. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2644 · Cited by 15
“Brain insulin plays an important role in protection against A-beta oligomers and phospho-tau neurotoxicity in AD patients [21,79].”
Yu, Z.-W., Liu, R., Li, X., Wang, Y., Fu, Y., Li, H.-Y., Yuan, Y., & Gao, X. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111294 · Cited by 14
Cimini, F. A., Marzia Perluigi, A., Barchetta, I., Cavallo, M. G., & Barone, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105574 · Cited by 17
Ma, L., Wei, Q., Deng, H., Zhang, Q., Li, G., Tang, N., Xie, J., & Chen, Y. (2013) · Journal of Neuroendocrinology · doi:10.1111/jne.12040 · Cited by 14
A variant in PPP4R3A protects against alzheimer‐related metabolic decline
Christopher, L., Napolioni, V., Khan, R. R., Han, S. S., Greicius, M. D., & Initiative, A. D. N. (2017) · Annals of Neurology · doi:10.1002/ana.25094 · Cited by 15
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease
Ettcheto, M., Busquets, O., Espinosa-Jiménez, T., Verdaguer, E., Auladell, C., & Camins, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200211121416 · Cited by 13
Dong, H., Yang, X., & Sun, Z. (2021) · Cognitive Neurodynamics · doi:10.1007/s11571-021-09705-x · Cited by 13
Onaolapo, A. Y., Ojo, F. O., Adeleye, O. O., Falade, J., & Onaolapo, O. J. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230102141154 · Cited by 14
Distribution of insulin in primate brain following nose‐to‐brain transport
Smith, K. R., Fan, J., Marriner, G. A., Gerdes, J. M., KESSLER, R. M., & Zinn, K. R. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12459 · Cited by 13
Lee, H., & Kim, E. Y. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01268-5 · Cited by 14
Tau Loss of Function, by Deletion or Aggregation, Contributes to Peripheral Insulin Resistance
Al‐Lahham, R., & Méndez, N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230392 · Cited by 13
Zhou, A. L., Swaminathan, S. K., Salian, V. S., Wang, L., Curran, G. L., Min, H.-K. P., Lowe, V. J., & Kandimalla, K. K. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00784 · Cited by 12
The neurodegeneration in Alzheimer disease and the prion protein
Forloni, G., Sclip, A., Borsello, T., & Balducci, C. (2013) · Prion · doi:10.4161/pri.23286 · Cited by 13
Khodabakhsh, P., Bazrgar, M., Mohagheghi, F., Parvardeh, S., & Ahmadiani, A. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13980 · Cited by 11
Cardiotrophin-1 (CT-1) Improves High Fat Diet-Induced Cognitive Deficits in Mice
Wang, D., Liu, L., Yan, J., et al. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1535-z · Cited by 12
Road From Nose to Brain for Treatment of Alzheimer: The Bumps and Humps
Kumar, R., Gulati, M., Singh, S. K., Sharma, D., & Porwal, O. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200708124726 · Cited by 12
Galizzi, G., Deidda, I., Amato, A., Calvi, P., Terzo, S., Caruana, L., Scoglio, S., Mulè, F., & Carlo, M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054731 · Cited by 14
Zamponi, E., & Pigino, G. F. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00350 · Cited by 12
“…transport inhibition induced by CK2 phosphorylation on KHCs which in turn will promote a reduction of kinesin-1 association to microtubules (MTs). activate CK2 both in vivo and in vitro (Chauhan et al., 1993; De Felice et al., 2009; Pigino et al., 2009; Tang et al., 2012; Ramser et al., 2013).”
BackgroundCopper and Neurotoxicity in Autism Spectrum Disorder
Santos, G., Borges, J. M. P., Ávila-Rodriguez, M., Gaino, S. B., Barreto, G. E., Rubio, É. P., Aguiar, R. M., Galembeck, E., Bromochenkel, C. B., & de Oliveira, D. M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191217091939 · Cited by 11
Current and Near-Future Treatment of Alzheimer’s Disease
Gąsiorowski, K., Brokos, B., Sochocka, M., Ochnik, M., Chojdak-Łukasiewicz, J., Zajączkowska, K., Fułek, M., & Leszek, J. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211202124239 · Cited by 13
Esparza, J. L., García, T. G., Gómez, M., Nogués, M. R., Giralt, M., & Domingo, J. L. (2010) · Biological Trace Element Research · doi:10.1007/s12011-010-8715-0 · Cited by 11
“It has been reported that the brain of AD patients is damaged by ROS [11, 19, 20 ].”
BackgroundBitel, C. L., Feng, Y., Souayah, N., & Frederikse, P. H. (2010) · BMC Physiology · doi:10.1186/1472-6793-10-18 · Cited by 11
“Moreover, this process has also been linked with insulin resistance [12,13].”
BackgroundBrito, G. N. O. (2009) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-1-7 · Cited by 11
Engin, A. B., Engin, D., Karakuş, R., Aral, A., Gülbahar, Ö., & Engin, A. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.09.038 · Cited by 11
The endocrine pancreas of old obesehyperglycemic mice.
Westman, S. (1968) · PubMed · Cited by 11
Wang, R., Peng, S., Zhu, J., Xu, Y., Wang, M., Zhang, L., Qiu, Y., Hou, D., Wang, Q., & Liu, R. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1651708 · Cited by 11
AboEl‐Azm, Y. H., El‐Samahy, M., Hendi, N. I., Arar, A., Yasen, N. S., Ramadan, S., Zedan, E. M., Al-dardery, N. M., & Khaity, A. M. (2023) · Journal of Clinical and Translational Research · doi:10.18053/jctres.09.202304.23-00013 · Cited by 11
Sarcopenia and Risk of Cognitive Impairment: Cohort Study and Mendelian Randomization Analysis
Sha, T., Zhang, Y., Wei, J., Li, C., Zeng, C., Lei, G., & Wang, Y. (2025) · JMIR Aging · doi:10.2196/66031 · Cited by 11
Proitsi, P., Lupton, M. K., Velayudhan, L., Hunter, G., Newhouse, S., Lin, K., Fogh, I., Tsolaki, M., Daniilidou, M., Pritchard, M., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.023 · Cited by 10
“There is also evidence that insulin signaling in the brain has effects on the key neuropathologic features of Alzheimer ’ s disease: the accumulation of b -amyloid peptide and neuro fi brillary tangles (De Felice et al., 2009).”
Marcos, A. B. S. W., Forner, S., Martini, A. C., Patrício, E. D. S., Clarke, J. R., da Costa, R., Felix-Alves, J., Vieira, V. J., de Andrade, E. L., Mazzuco, T. L., et al. (2015) · Journal of Neurotrauma · doi:10.1089/neu.2015.3877 · Cited by 10
Ayan, E. B., & DeMi̇rci̇, H. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666220610150342 · Cited by 14
Chang, X.-H., Liang, L.-N., Zhan, L.-B., Lu, X.-G., Shi, X., Qi, X., Feng, Z.-L., Wu, M.-J., Sui, H. X., Zheng, L.-P., et al. (2013) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-13-161 · Cited by 10
Spatial dynamics of the insulin receptor in living neurons
Gralle, M., Labrecque, S., Salesse, C., & Koninck, P. D. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14950 · Cited by 10
“A patchy somatodendritic distribution has been reported on non-permeabilized cultured neurons (De Felice et al., 2009; Zhao et al., 2009) using an insulin receptor subunit α (extracellular) antibody, which, however, has never been demonstrated to discriminate between insulin receptor and…”
BackgroundInsulin signaling as a therapeutic target in Alzheimer’s disease: Efficacy of apomorphine
Ohyagi, Y., & Takei, S. (2020) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.12369 · Cited by 10
He, Z., Zheng, L. P., Zhao, X., Li, X., Xue, H., Zhao, Q., Ren, B., Li, N., Ni, J., Zhang, Y., et al. (2022) · Biological Trace Element Research · doi:10.1007/s12011-021-02938-1 · Cited by 10
Chen, Z., Li, J., Sun, J., & Ma, L. (2013) · Journal of Neuroimaging · doi:10.1111/jon.12059 · Cited by 10
Querfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K. (2022) · PLOS ONE · doi:10.1371/journal.pone.0261696 · Cited by 9
“The inhibitory effect of Aβ42 oligomers on hippocampal LTP and PI3K/Akt is reversed by insulin [47, 48].”
BackgroundThe Role of Insulin Dysregulation in Aging and Alzheimer’s Disease
Craft, S. (2010) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-642-04300-0_8 · Cited by 9
RIP at the Synapse and the Role of Intracellular Domains in Neurons
Lee, Y. J., & Ch’ng, T. H. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08556-4 · Cited by 11
Johnson, M. A. (2012) · Materials and Methods · doi:10.13070/mm.en.2.115 · Cited by 12
Metadata
- Authors
- De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L.
- Affiliations
- Department of Neurobiology and Physiology, Northwestern University, Evanston, IL 60208; and
- Universidade Federal do Rio de Janeiro (BR)
- Instituto de Bioquímica Médica and
- Northwestern University (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-02-10
- Volume
- 106
- Issue
- 6
- Pages
- 1971-1976
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2634809
- OpenAlex
- W2097335530
- Semantic Scholar
- f83fd1ab92993abebf2d284fe60d8398949b7908
- Cited by
- 657
- References
- 51
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 17 · 2023: 20 · 2022: 30 · 2021: 41 · 2020: 41 · 2019: 42 · 2018: 44 · 2017: 42 · 2016: 44 · 2015: 53 · 2014: 44 · 2013: 57 · 2012: 46
- FWCI
- 31.69
- Type
- journal article
- Language
- en
- Update notices
- correction (2009-05-05)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation for the National Institutes of Health
- Howard Hughes Medical Institute
- Alzheimer's Association
- American Health Assistance Foundation
- National Institute on Aging (R01AG022547, R01-AG22547, R01-AG18877, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, insulin signaling, insulin receptor, synaptic plasticity, oxidative stress, CaMKII, casein kinase 2, rosiglitazone, insulin receptor tyrosine kinase, hippocampal neurons, memory loss
- MeSH terms
- Rosiglitazone, Alzheimer Disease, Animals, Cattle, Cells, Cultured, Hippocampus, Humans, Insulin, Neurons, Protein Binding, Receptor, Insulin, Synapses, Signal Transduction, Amyloid beta-Peptides, Oxidative Stress, Dimerization, Protective Agents, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
